Objective
=========

Septic shock is characterized by enhanced hepato-splanchnic blood flow resulting from increased metabolic activity. This hypermetabolism may lead to mismatch of regional O~2~ supply and demand reflected by increased CO~2~-gradients and lactate/pyruvate ratios. In patients after cardiac surgery dopexamine is known to increase splanchnic perfusion. Therefore, we studied the effect of dopexamine on regional CO~2~-gradients and energy balance in patients with septic shock.

Patients and methods
====================

Twelve patients with septic shock were studied. Cardiac index (CI) was ≥ 3 l/min/m^2^ and noradrenaline ≥ 0.04 μg/kg×min^-1^ was infused to maintain mean arterial pressure (MAP) ≥ 60 mmHg. In addition to routine systemic hemodynamics and gas exchange we inserted a Swan Ganz catheter into a hepatic vein to measure splanchnic blood flow (Qspl) using primed continous infusion of indocyanine green (ICG) dye. Moreover, we assessed splanchnic lactate uptake (Fick principle), hepatic venous lactate/pyruvate ratio as well as PCO~2~ (PCO~2~hv), splanchnic O~2~ delivery (DO~2~spl) and consumption (VO~2~spl). The gatric mucosal PCO~2~ (PCO~2~gm) was determined via a nasogastric tube. Measurements were done before, during and after dopexamine infusion. Data were obtained after 90 min of hemodynamic steady-state. Dopexamine was titrated (1--4 μg/kg×min^-1^) to obtain a 30% increase in CI.

Results
=======

See Table.

Conclusion
==========

The unpredictable changes in the metabolic state and regional PCO~2~ gradients after a dopexamine-induced increase in DO~2~spl, underscores the independent response of hepato-splanchnic perfusion and metabolism to therapeutic interventions.

  Median/range                          Baseline        Dopexamine          Baseline
  ------------------------------------- --------------- ------------------- --------------------
  DO~2~ index spl (1/min/m^2^)          116 (211-39)    130 (323-38)^\#^    120 (233-34)
  VO~2~ index spl (1/min/m^2^)          66 (88-17)      62 (142-14)         61 (113-16)
  Lactate utilisation (μmol/m^2^/min)   239 (876-358)   425 (1448-590)      345 (2040 to -578)
  Lactate/pyruvate ratio                27 (61-20)      30 (185-22)         42 (75-21)
  PCO~2~gm-PCO~2~art (kPa)              2.8 (5.2-0.0)   2.2 (4.2 to -0.3)   2.8 (4.5-0.3)
  PCO~2~mv-PCO~2~art (kPa)              0.9 (1.5-0.1)   0.6 (1-0.1)         0.8 (1.3-0.3)
  PCO~2~hv-PCO~2~art (kPa)              1.2 (2.3-0.3)   0.8 (1.7 to-0.1)    1.1 (1.8-0.5)

Statistics: Friedman-test; Wilcoxon-test; ^\#^*P* \< 0.05 versus baseline
